Table 1.
No. | Age | Sex | Laterality | Post B2 Histological Dx | PAC (ng/dL) | PRA | ARR | Captopril Challenge ARRa | Lateralization Index in AVS Before Cosyntropin Loading | Lateralization Index in AVS After Cosyntropin Loading | Serum K | Preoperation Status |
Postoperation Status |
Spironolactone Body | Paradoxical Hyperplasia | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Left | Right | SBP | DBP | No. of Antihypertensive Drugs | SBP | DBP | No. of Antihypertensive Drugs | Nodule | ZG | ||||||||||||
1 | 25 | M | Bilateral | DH | DH | 11.4 | 0.8 | 14.3 | 2.1 | 2.77 | 1.21 | 4.4 | 122 | 62 | 7 | 117 | 71 | 1 | - | - | |
2 | 27 | F | Bilateral | DH | DH | 44.6 | 2.7 | 16.5 | 5.1 | 1.5 | 1.92 | 4.3 | 112 | 68 | 1 | 120 | 82 | 0 | - | - | |
3 | 32 | F | Bilateral | DH | DH | 13.9 | 0.6 | 23.2 | 1.8 | 2.19 | 1.06 | 3.4 | 113 | 67 | 3 | 115 | 87 | 0 | - | - | |
4 | 43 | F | Bilateral | DH | DH | 38.2 | 1.8 | 21.2 | 4.3 | 1.51 | 1.35 | 4 | 120 | 82 | 5 | 111 | 73 | 1 | + | + | |
5 | 44 | M | Bilateral | DH | DH | 14.8 | 0.4 | 37 | 18.2 | 7.38 | 1.23 | 4.7 | 119 | 74 | 4 | 120 | 69 | 0 | + | + | |
6 | 44 | F | Bilateral | DH | DH | 19.9 | 2.3 | 8.7 | 5.2 | 1.33 | 1.03 | 3.4 | 119 | 64 | 3 | 118 | 82 | 1 | - | - | |
7 | 44 | F | Bilateral | DH | DH | 19.7 | 0.4 | 49.3 | 10.7 | 1.71 | 1.49 | 4.7 | 111 | 76 | 2 | 127 | 82 | 0 | - | - | |
8 | 42 | M | Unilateral | Not resected | DH | 17.4 | 0.7 | 24.9 | 9.1 | 1.41 | 2.71 | 4.8 | 120 | 70 | 8 | 117 | 84 | 0 | - | - | |
9 | 49 | M | Unilateral | Not resected | DH | 47 | 0.1 | 470 | 171 | 9.73 | 18.7 | 3.1 | 118 | 88 | 4 | 110 | 74 | 0 | - | + | |
10 | 51 | M | Bilateral | Not resected | DH | 15.6 | 0.7 | 22.3 | 6 | 2.22 | 1.67 | 3.5 | 122 | 84 | 3 | 103 | 70 | 0 | + | - | |
11 | 61 | M | Bilateral | Not resected | DH | 13 | 0.5 | 26 | 46.5 | 6.49 | 2.47 | 4.3 | 119 | 69 | 2 | 118 | 74 | 0 | + | - | |
12 | 47 | F | Bilateral | DH | Not resected | 16.9 | 0.6 | 28.2 | 46.3 | 3.77a | 1.52a | 3.5 | 99 | 66 | 3 | 98 | 81 | 0 | - | - | |
13 | 32 | M | Bilateral | MN | MN | 7.2 | 0.3 | 24 | 5.2 | 2.18 | 1.22 | 4.1 | 121 | 86 | 5 | 119 | 78 | 1 | - | - | Weak/weak |
14 | 36 | F | Bilateral | MN | MN | 17.4 | 0.5 | 34.8 | 25.7 | 1.54 | 2.03 | 4.8 | 120 | 86 | 2 | 129 | 88 | 1 | - | - | +/+ |
15 | 37 | F | Bilateral | MN | MN | 11.3 | 0.4 | 28.3 | 39.5 | 1.26 | 1.33 | 4.4 | 115 | 59 | 4 | 119 | 76 | 1 | + | - | +/+ |
16 | 40 | M | Bilateral | MN | MN | 13.8 | 0.1 | 138 | 35.7 | 1.63 | 1.51 | 3.9 | 126 | 81 | 6 | 126 | 86 | 1 | + | - | −/− |
17 | 47 | F | Bilateral | MN | MN | 11 | 0.2 | 55 | 48.5 | 2.47 | 1.61 | 3.5 | 126 | 88 | 4 | 100 | 73 | 1 | - | - | +/+ |
18 | 30 | M | Bilateral | Not resected | MN | 14.4 | 1.6 | 9 | 4.6 | 4.87 | 1.43 | 3.7 | 143 | 88 | 6 | 139 | 84 | 3 | + | - | Weak |
19 | 43 | F | Unilateral | Not resected | MN | 15.5 | 0.8 | 19.4 | (1.3/47.7) 36.7b | 3.04 | 7.95 | 3.3 | 125 | 97 | 1 | 123 | 98 | 0 | - | - | + |
20 | 49 | F | Bilateral | Not resected | MN | 18.4 | 0.7 | 26.3 | N/A | 2.67 | 1.71 | 3.3 | 136 | 84 | 1 | 133 | 89 | 0 | - | - | Weak |
21 | 61 | F | Unilateral | Not resected | MN | 10.3 | 0.4 | 25.8 | (0.9/52.8) 58.6b | 5.27 | 46.8 | 4.2 | 164 | 103 | 1 | 146 | 83 | 0 | - | - | + |
22 | 61 | F | Unilateral | Not resected | MN | 36.2 | 0.3 | 120.7 | (0.3/36.2) 120.7b | 3.41 | 10.5 | 3.9 | 158 | 98 | 1 | 156 | 90 | 0 | - | - | + |
23 | 69 | M | Bilateral | Not resected | MN | 9.9 | 0.4 | 24.8 | 12.3 | 2.53 | 1.63 | 3.9 | 123 | 84 | 4 | 144 | 87 | 2 | + | - | + |
24 | 69 | F | Unilateral | Not resected | MN | 23.5 | 0.2 | 117.5 | 28.7 | 11.1 | 4.91 | 4.5 | 124 | 66 | 2 | 116 | 63 | 0 | - | - | + |
25 | 36 | M | Unilateral | MN | Not resected | 20.2 | 0.4 | 50.5 | 15.2 | 3.19 | 4.6 | 4 | 116 | 70 | 5 | 133 | 95 | 0 | - | - | + |
Twenty-five consecutive cases with available resected adrenals from 2005 to 2015 that met the following criteria were retrospectively selected from 2 institutions: clinical hypertension associated with aldosterone hypersecretion, improvement of hypertensive status according to blood pressure, and the number of antihypertensive drugs before and after surgery. Twenty-one cases were from Tohoku University Hospital (from 2005 to 2015), and 4 cases from Asahikawa Red Cross Hospital (from 2014 to 2015). Biological PA confirmation was determined by the captopril loading test (Tohoku University), and the flosemide loading test followed by walking (Asahikawa Red Cross Hospital). All cases were negative according to cross-sectional imaging. No cases had microAPAs (as assessed by histology and CYP11B2 IHC). All patients underwent unilateral or bilateral adrenal resection for persistent hypertension resistant to multiple antihypertensive medications, cardiovascular complications, juvenile hypertension, or some adrenal gland surface irregularities according to cross-sectional imaging. Lateralization of all cases was clinically categorized by AVS, using the cutoff value of 2.6 of lateralization index after adrenocorticotropic hormone loading (17). Twenty-five cases were classified as ZG hyperplasia, similar to that seen adjacent to APAs. As in APA cases, ZGs are morphologically hyperplastic but negative for CYP11B2, suggesting the inability to produce aldosterone. In addition, ZG paradoxical hyperplasia was generally less pronounced in MN than APA. Adjacent ZGs in some MN cases demonstrated even atrophic changes. Spironolactone bodies were detected both in nodular and nonnodular cortical cells in DH, but only in cortical cells of micronodules in MN, and these cells harboring spironolactone bodies were positive for CYP11B2.
Abbreviations: ARR, aldosterone renin ratio; DBP, diatolic blood pressure; Dx, diagnosis; F, female; M, male; N/A, not available; PAC, plasma aldosterone concentration; PRA, plasma renin activity; SBP, systolic blood pressure.
Canulation failure.
PRA/PAC (ARR) value 2 hours after flosemide loading followed by walk.